Summit Therapeutics Inc.
ivonescimab
non-small cell lung cancer (NSCLC)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ivonescimab for non-small cell lung cancer (NSCLC) is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“HARMONi: BLA Decision in 2L+ EGFRm NSCLC expected”